Seaport Therapeutics, Inc.
SPTX
Positions held
Your positionsSPTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Seaport Therapeutics operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- The company's market cap stands at approximately $929.83 million, indicating a substantial valuation in the biotech space.
- Analysts have given a strong buy recommendation, with a target mean price of $38.29, suggesting significant upside potential.
- Despite its potential, Seaport Therapeutics has reported no revenue, indicating challenges in monetizing its innovations.
- The company has a negative net income of -25.41 million for Q1 2026, reflecting ongoing financial struggles.
- Current market signals indicate a strong sell with a score of -16.00, suggesting bearish sentiment among investors.
Fundamentals
| Market cap | $958.73M | Enterprise value | $690.44M | Trailing P/E | — | Forward P/E | -6.96 |
| PEG | — | Price / book | 2.27 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.01 |
| Current ratio | 18.00 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $38.29 |
| 52w high | $28.38 | 52w low | $14.85 |
Quarterly
| 2026-Q1 | 2025-Q1 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$25.4M | -$13.1M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$27.5M | -$16.2M |
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$74.9M | -$46.9M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$87.3M | -$52.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Seaport Therapeutics Doses First Patient in Phase 2a GlyphAgo Trial
2026-09-25 · Raymond James Initiates Seaport Therapeutics at Strong Buy
2026-09-22 · PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
2026-09-22 · PureTech Health H1 Earnings Call Highlights
2026-09-14 · Seaport Therapeutics to Participate in September Investor Conferences
2026-09-09 · Sector Update: Healthcare Stocks Mixed Premarket Wednesday
2026-09-09 · Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial
Price (daily)
Full chart · RSI · MACD · patterns